Unknown

Dataset Information

Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation.


ABSTRACT: Limited early evidence indicates thermal ablation of non-small cell lung cancer (NSCLC) may induce alterations to the immune response that could enhance the efficacy of immunotherapy with immune checkpoint inhibitor therapy. This study reports pilot data demonstrating increased programmed death-ligand 1 (PD-L1) expression on tumour cells in response to bronchoscopic thermal vapour ablation. Five patients underwent bronchoscopic thermal vapour ablation under a treat-and-resect protocol, as part of a clinical safety and feasibility study, with lobectomy performed five days after thermal vapour ablation. PD-L1 (clone SP263) immunohistochemistry (IHC) tumour proportion score (TPS) was assessed on both baseline diagnostic biopsy specimens, and post-ablation resection specimens in five patients

SUBMITTER: Rangamuwa K 

PROVIDER: S-EPMC8264342 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature